PAHC Form 4: BFI Co. and Jack Bendheim disclose 09/30/2025 sales
Rhea-AI Filing Summary
Insider sales reported for PHIBRO ANIMAL HEALTH CORP (PAHC). On 09/30/2025 the filing shows dispositions of Class A common stock by BFI Co., LLC and Jack Bendheim. BFI reported a sale of 20,664 shares at a weighted average price of $40.38 (individual trade prices ranged $40.00–$40.635) and Jack Bendheim reported a sale of 16,840 shares.
The filing states the BFI sales were effected under a Rule 10b5-1 trading plan adopted May 30, 2025. After the reported transactions, BFI is shown as beneficially owning 40,674 shares, and Jack Bendheim directly holds the 16,840 shares he sold before the disposition shown on this Form 4. The filing is signed by an attorney-in-fact on behalf of both reporting persons.
Positive
- Sales conducted under a Rule 10b5-1 trading plan, as disclosed in footnote 1
- Weighted average sale price provided ($40.38) and explicit price range ($40.00–$40.635) for transparency
- Filing discloses ownership relationships and disclaimers regarding BFI and Jack Bendheim
Negative
- Total shares disposed reported: 37,504 shares (20,664 by BFI Co., LLC and 16,840 by Jack Bendheim)
- Insider selling on a single date (09/30/2025) could be viewed as a material change in insider holdings for investors
- Post-transaction beneficial ownership reduced for BFI to 40,674 shares as stated
Insights
TL;DR: Reporting persons sold a total of 37,504 Class A shares on 09/30/2025 at a weighted average price of $40.38 under a 10b5-1 plan.
The filing documents two separate dispositions: 20,664 shares by BFI Co., LLC and 16,840 shares by Jack Bendheim. The weighted average price for the BFI sales is disclosed as $40.38 with an indicated price range of $40.00 to $40.635. BFI remains a beneficial owner of 40,674 shares after the transactions. All details provided are transactional and procedural; there is no earnings or corporate financial data in this Form 4.
TL;DR: Transactions were executed under a Rule 10b5-1 plan and properly disclosed on Form 4; filing includes required explanatory footnotes.
The report includes explanatory footnotes stating the sales were under a May 30, 2025 10b5-1 trading plan and provides a weighted average sale price plus the range of execution prices. It identifies ownership relationships and disclaims of beneficial ownership where applicable. The filing is signed by an attorney-in-fact for both reporting persons, meeting signature disclosure norms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 20,664 | $40.38 | $834K |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.635. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The reported securities are directly held by Jack Bendheim.
